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Abstract
Background: Non-high-density lipoprotein cholesterol (non-HDL-C) measures all atherogenic apolipoprotein B-
containing lipoproteins and predicts risk of cardiovascular diseases (CVD). The association of non-HDL-C with risk of
death from CVD in diabetes is not well understood. This study assessed the hypothesis that, among adults with
diabetes, non-HDL-C may be related to the risk of death from CVD.
Methods: We analyzed data from 1,122 adults aged 20 years and older with diagnosed diabetes who participated
in the Third National Health and Nutrition Examination Survey linked mortality study (299 deaths from CVD
according to underlying cause of death; median follow-up length, 12.4 years).
Results: Compared to participants with serum non-HDL-C concentrations of 35 to 129 mg/dL, those with higher
serum levels had a higher risk of death from total CVD: the RRs were 1.34 (95% CI: 0.75-2.39) and 2.25 (95% CI:
1.30-3.91) for non-HDL-C concentrations of 130-189 mg/dL and 190-403 mg/dL, respectively (P = 0.003 for linear
trend) after adjustment for demographic characteristics and selected risk factors. In subgroup analyses, significant
linear trends were identified for the risk of death from ischemic heart disease: the RRs were 1.59 (95% CI: 0.76-3.32)
and 2.50 (95% CI: 1.28-4.89) (P = 0.006 for linear trend), and stroke: the RRs were 3.37 (95% CI: 0.95-11.90) and 5.81
(95% CI: 1.96-17.25) (P = 0.001 for linear trend).
Conclusions: In diabetics, higher serum non-HDL-C concentrations were significantly associated with increased risk
of death from CVD. Our prospective data support the notion that reducing serum non-HDL-C concentrations may
be beneficial in the prevention of excess death from CVD among affected adults.
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Introduction
Non-high-density lipoprotein cholesterol (non-HDL-C)
concentration is a composite marker of several athero-
genic lipoproteins, including low-density lipoprotein
(LDL), very-low-density lipoprotein (VLDL), intermedi-
ate-density lipoprotein (IDL), and lipoprotein (a) [1].
Non-HDL-C concentration can be measured by
subtracting high-density lipoprotein cholesterol (HDL-
C) concentration from total serum cholesterol concen-
tration and it may be used as a candidate biometrical
equivalent to apolipoprotein B100 in diabetes [2]. Serum
total cholesterol and LDL cholesterol have been used as
major laboratory measures in clinical practice to assess
cardiovascular risk in the general population and disease
management and prognosis in patients [1]. Recent stu-
dies, however, have shown that non-HDL-C concentra-
tion is similar to or better than LDL-C alone in the
prediction of cardiovascular disease (CVD) incidence
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prediction of CVD incidence among people with type 2
diabetes [8-10].
People with diabetes have an excess risk of incidence
and mortality from CVD [11,12], however whether non-
HDL-C concentration predicts CVD mortality among
people with diabetes is not well understood. A few pre-
vious studies have assessed the associations of non-
HDL-C with risk of death from coronary heart disease
(CHD) [13] and CVD [14], but reported conflicting
results. Demographic differences in study cohorts, small
sample sizes, or short follow-up periods may be attribu-
table to inconsistency in previous study findings. To
determine the association between serum non-HDL-C
concentration and risk of death from CVD in a larger,
more racially diverse cohort of diabetic participants over
al o n g e rs t u d yp e r i o d ,w ea n a l y z e db a s e l i n ed a t af r o m
the Third National Health and Nutrition Examination
Survey (NHANES III) of U.S. adults aged 20 years and
older and the linked mortality data on NHANES III
participants.
Methods
Study population
The NHANES III (1988-1994) survey recruited study
participants using a multistage, stratified sampling pro-
cess designed to produce a survey sample representative
of the civilian non-institutionalized U.S. population [15].
The NHANES III survey underwent Institutional Review
Board approval, and written informed consent was
received from all participants. After being interviewed at
their homes, participants were invited to a mobile exam-
ination center where they had a clinical examination and
provided a blood sample. Response rates were 86% for
the household interviews and 78% for the medical exam-
inations [16]. Of 1,262 survey participants who had diag-
nosed diabetes and attended a mobile examination
center, 1,179 (93.4%) provided serum samples for non-
HDL-C measurements. After exclusion of participants
who had missing data on covariates (n = 57), our study
cohort consisted of 1,122 NHANES III participants
(88.9% of all participants who attended a mobile exami-
nation center).
Diabetes status and duration
Diagnosed diabetes was ascertained by asking partici-
pants, “Have you ever been told by a doctor that you
have diabetes?” Responses were coded as “yes,”“ yes, but
female told only during pregnancy,” or “no.” Ad i a b e t e s
history restricted to pregnancy was coded as “no” dia-
betes. Diabetes duration in years was determined by
subtracting age at diagnosis of diabetes from age at
baseline examination.
Laboratory procedures
A detailed description of laboratory procedures has been
published elsewhere [17]. In brief, serum samples were
aliquoted, stored at -70°C, and shipped on dry ice to the
NHANES laboratory at the Centers for Disease Control
and Prevention. Total serum cholesterol was measured
enzymatically in a series of coupled reactions that
hydrolyze cholesterol esters and oxidize the 3-OH cho-
lesterol group. HDL-C concentrations were measured
after the precipitation of the other lipoproteins with a
polyanion/divalent cation mixture. Both total cholesterol
and HDL-C analyses were performed with the Hitachi
704 Analyzer (Boehringer Mannheim Diagnostics, India-
napolis, Indiana). Triglyceride concentrations were mea-
sured enzymatically in serum after specimens were
hydrolyzed to glycerol through a series of coupled reac-
tions. Serum non-HDL-C concentrations were calcu-
lated by subtracting HDL-C concentrations from total
cholesterol concentrations. Serum LDL-C concentration
were estimated from measured values of total choles-
terol, triglycerides, and HDL-C according to the Friede-
wald formula (i.e., CLDL-C = CTotal cholesterol - CHDL-C -
Triglycerides/5) among participants with triglycerides ≤
400 mg/dL [17,18].
C-reactive protein (CRP) was measured at the Depart-
ment of Laboratory Medicine, University of Washington,
by using latex-enhanced nephelometry (Behring Diag-
nostics, Inc., Somerville, New Jersey). The continuum of
CRP concentrations was categorized to two groups: <
3.0 mg/L and ≥ 3.0 mg/L. The concentrations of gly-
cated hemoglobin A1c (% ) were measured at the Dia-
betes Diagnostic Laboratory at the University of
Missouri, Columbia, Missouri by using the ion-
exchange, high-performance liquid chromatography on
the Diamat Analyzer System (Bio-Rad Laboratories, Her-
cules, California). Serum creatinine concentrations were
measured at the White Sands Research Center (Coul-
ston Foundation) laboratory (Alamogordo, New Mexico)
by using the kinetic alkaline picrate reaction method on
a Roche/Hitachi 737 analyzer (Roche Diagnostics, India-
napolis, Indiana). Glomerular filtration rate (GFR) was
estimated with the new equation developed by the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) on the basis of standardized serum creati-
nine level (standard creatinine = - 0.184 + 0.960 ×
NHANES III uncalibrated serum creatinine) [19,20].
Estimated GFR is reported in ml/minute per 1.73 m
2 of
body surface area.
Demographic characteristics and physical examination
measures at baseline
Participants’ age (years), race/ethnicity (non-Hispanic
white, non-Hispanic black, Mexican American, and
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school, high school, and beyond high school), smoking
status (current smoker, former smoker, and never
smoked), alcohol consumption (times in the previous
month), and use of prescribed medicine to lower blood
cholesterol (yes, no) were determined by self reports of
participants. Physical activity level was determined by
participants’ self-reported frequency of engaging in spe-
cific types of leisure-time exercise or activities during
the previous month multiplied by the rate of energy
expenditure (intensity rating) for those activities accord-
ing to a standardized coding method [21]. Participants’
body mass index (BMI; weight [kg]/height
2 [m]) was cal-
culated from their measured weight and height. The
mean blood pressure was calculated as the average of
the second and third readings for those who had three
measurements, the second reading for those who had
two measurements, and the on l yr e a d i n gf o rt h o s ew h o
had one measurement [22].
Linked mortality data through 2006
The NHANES III participants with sufficient identifying
data were matched to the National Death Index (NDI)
to determine their survival status through 2006 [23].
The National Center for Health Statistics (NCHS) per-
formed linkage with probabilistic matching between
NHANES III and NDI data and reviewed death certifi-
cates to ensure that deaths reported in the NDI were
matched to the correct NHANES III participants. We
used a standardized list of 113 causes based on Interna-
tional Classification of Diseases, Tenth Revision (ICD-
10) codes to determine decedents’ underlying cause of
death [24]. We divided CVD into the subcategories of
ischemic heart disease (IHD), stroke, and other CVD.
Statistical analysis
We first examined the population distribution of serum
non-HDL-C concentrations by sex and age. We divided
the continuum of serum non-HDL-C concentrations
into three categories (<130, 130-189, and ≥ 190 mg/dL)
according to the Third Report of the National Choles-
terol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (NCEP ATP III) [25]. We compared baseline
demographic characteristics and cardiovascular risk fac-
tors of participants according to these three levels using
2-sample t tests.
We conducted Cox proportional hazard regression
analysis to estimate relative risks (hazard ratios) and
95% confidence interval (CI) for death from total CVD,
IHD, stroke, and other CVD in which we treated serum
non-HDL-C as a categorical variable with 3 levels. We
used age in months as the time scale in survival analyses
with left truncation (i.e., participants entered into the
cohort at different ages). Participants’ age in months at
the end of follow-up was determined by adding their
age in months at baseline examination to the number of
months they were followed. We provided unadjusted
risk estimates and adjusted risk estimates by controlling
for the selected potential confounders. We used t tests
with orthogonal polynomial coefficients to test for linear
trends in relative risks in the Cox regression models. To
account for the possible nonlinear association between
serum non-HDL-C concentrations and risk of death
from CVD, we also estimated relative risks by perform-
ing Cox proportional hazard regression analyses using
serum non-HDL-C concentrations as a continuous vari-
able and adding its cubic regression spline term with
three knots [26].
To further examine whether the association between
serum non-HDL-C concentration and risk of death
from CVD may be consistent in sub-populations, we
conducted subgroup analyses using a 10 mg/dL increase
in non-HDL-C as the predictor variable, stratified by
demographic characteristics and selected CVD risk fac-
tors. To ensure adequate sample size in each level of
stratification variables, we dichotomized the following
stratification variables: age (20-64 y versus 65 y), race
(non-Hispanic white versus non-white), educational
attainment (<high school versus high school or beyond),
diabetes duration (<10 y versus ≥ 10 y), follow-up length
(<10 y versus ≥ 10 y), smoking status (current or former
smoker versus never smoked), We used Wald c
2 tests to
assess the interactions between serum non-HDL-C con-
centrations and all stratification variables on the risk of
death from IHD.
We conducted sensitivity analyses by replicating the
main analyses using an alternative definition of diabetes
based on both self-reported diabetes diagnosis and gly-
cated hemoglobin A1C level ≥ 6.5% among adults with-
out a diagnosis of diabetes. We also compared the
relative risk of death from CVD between non-HDL-C
and LDL-C, using a restricted sample of adults who
attended the morning session of a mobile examination
center, had fasted at least 8 hours, and had a valid LDL-
C value (n = 366).
Results of 2-tailed t tests used in two groups or c
2
tests used in 2-way comparisons were considered to be
statistically significant if P values were less than 0.05
and estimates of relative risks were significantly different
from 1 if the 95% CI did not include 1. Data were ana-
lyzed using the SAS System for Windows (Release 9.2)
(SAS Institute Inc., Cary, North Carolina) and SUDAAN
software (Release 10, Research Triangle Institute,
Research Triangle Park, NC). In all analyses, sample
weights were used to account for the varying probabil-
ities of complex sampling design and nonresponse and
produce nationally representative estimates.
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Of the 1,122 eligible NHANES III adult participants
with diagnosed diabetes and with no missing data on all
selected variables in our study, 655 were found to have
died over a median follow-up period of 12.4 years
(Table 1). Of those who died from all causes, 299 died
from CVD (46.4%; including 182 deaths from IHD, 50
deaths from stroke, and 67 deaths from other CVD).
The mean concentration of serum non-HDL-C was
174.25 mg/dL (±2.89 mg/dL) for the entire cohort,
including 165.45 mg/dL (±0.4.40 mg/dL) among men,
and 182.02 mg/dL (±2.69 mg/dL) among women (P <
0.001 for difference by sex). We found significant differ-
ences by serum non-HDL-C concentration levels in the
following characteristics: mean body mass index, systolic
blood pressure, serum HDL-C concentration, distribu-
tion of study participants by sex, CRP concentration ≥
3.0 mg/L, and use of prescribed medicine to lower
blood cholesterol (all P < 0.05) (Table 2). Men had a
higher rate of using prescribed medicine to lower blood
cholesterol than women (10.4% vs. 7.7%, P =0 . 3 8 ) ,
albeit the difference in the rates did not reach statistical
significance.
We found a significant trend in the unadjusted relative
risk of death from total CVD, IHD, and stroke (all P
<0.01 for linear trend) (Table 3). After adjusting for the
demographic characteristics and CVD risk factors pre-
sented in Table 2, the significant association persisted
(all P <0.01 for linear trend). No significant association
was found between serum non-HDL-C concentration
and risk of death from other CVD.
We found an elevated relative risk of death from CVD
for each 10 mg/dL increase in serum non-HDL-C con-
centration in most subgroups stratified by demographic
characteristics and CVD risk factors. However, the RR
did not reach statistical significance at a =0 . 0 5l e v e li n
the following subgroups: women, non-whites, partici-
pants with educational attainment of high school or
above, adults with a diagnosis of diabetes ≥ 10 years,
adults with no leisure-time physical activity, adults with
a GFR < 60 mL/min per 1.73 m
2,a d u l t sw i t haC R P
level ≥ 3.0 mg/L, and adults with a serum glycated
hemoglobin A1C ≥ 7.0% (P values ranging from 0.062 to
0.68) (Table 4). We detected a significant interaction
between serum non-HDL-C concentrations and the fol-
lowing variables: sex, age, diabetes duration, follow-up
length, alcohol consumption, and systolic blood pressure
(all P values <0.05).
By modeling non-HDL-C as a continuous variable and
adding its cubic regression spline term with 3 knots, we
Table 1 Number of Deaths from CVD among Adults Aged ≥ 20 Years with Diagnosed Diabetes in the United States,
the Third National Health and Nutrition Examination Survey Linked Mortality Study, 1988-2006
Cause of Death List of 113
Causes of Death
a
No. and Rate of Death
(1/1,000 person-year)
Total Cohort
(N = 1,122)
Serum non-HDL-C
Concentration (mg/dL)
b
35-129 130-189 190-403
Person-years (sample) 11,807 1,915 6,222 3,670
Person-years (weighted) 89,423,467 14,290,472 45,912,850 29,220,145
All causes 1-135 No. (sample) 655 125 303 227
No. (weighted) 4,197,413 601,058 1,906,185 1,690,170
Rate (weighted) 46.9 42.1 41.5 57.8
Total CVD 53-74 No. (sample) 299 50 137 112
No. (weighted) 1,946,876 217,843 819,108 909,926
Rate (weighted) 21.8 15.2 17.8 31.1
IHD 58-63 No. (sample) 182 26 90 66
No. (weighted) 1,225,668 124,344 531,179 570,144
Rate (weighted) 13.7 8.7 11.6 19.5
Stroke 70 No. (sample) 50 9 20 21
No. (weighted) 262,765 11,748 121,332 129,685
Rate (weighted) 2.9 0.8 2.6 4.4
Other CVD 53-57, 64-69, 71-74 No. (sample) 67
c 15 27 25
No. (weighted) 458,443 81,750 166,597 210,096
Rate (weighted) 5.1 5.7 3.6 7.2
Abbreviations: CVD, cardiovascular disease; IHD, ischemic heart disease; non-HDL-C, non-high-density lipoprotein cholesterol.
a The list of 113 causes of death was developed based on ICD-10 codes [24].
b To convert HDL-C or non-HDL-C concentrations in mg/dL to concentrations in mmol/L, multiply by 0.02586.
c Include 3 cases of hypertensive heart disease, 1 hypertensive heart and renal disease, 18 cases of heart failure, 30 cases of all other forms of heart disease, 5
cases of essential (primary) hypertension and hypertensive renal disease, 5 cases of atherosclerosis, 1 case of aortic aneurysm and dissection, and 4 cases of
other diseases of arteries, arterioles and capillaries.
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ship of serum non-HDL-C concentrations to risk of
death from total CVD (Figure 1, A), IHD (Figure 1, B),
and stroke (Figure 1, C). By modeling non-HDL-C as a
categorical variable with five levels, we found that peo-
ple with a serum non-HDL-C concentration of 190-219
mg/dL or ≥ 220 mg/dL had a significantly elevated
risk of death from total CVD( F i g u r e2 ,A )a n ds t r o k e
(Figure 2, C). People with a serum non-HDL-C concen-
tration of ≥ 220 mg/dL had a significantly elevated risk
of death from IHD (Figure 2, B). We did not detect a
significant association between the non-HDL-C concen-
tration and risk of death from other CVD (Figure 1, D
and Figure 2, D).
The results of the sensitivity analyses by including
adults with undiagnosed diabetes showed that the
strengths of the associations between non-HDL-C and
risk of death from total CVD, IHD, stroke, and other
CVD attenuated slightly, but the patterns and linear
trends persisted (Table 5). By using available data of
LDL-C among adults who attended the morning session
of a mobile examination center, we found that the rela-
tive risk of death from total CVD, IHD, stroke, and
other CVD for a 10 mg/dl change was similar between
non-HDL-C and LDL-C in both unadjusted and
adjusted estimates (Table 6).
Discussion
In this prospective study of a nationally representative
sample of U.S. adults with diagnosed diabetes over a
median follow-up length of 12.4 years, we found that
higher serum non-HDL-C concentrations were strongly
associated with increased risk of death from total CVD,
IHD, and stroke. The significant association between a
10 mg/dL increase in serum non-HDL-C concentration
and increased risk of death from total CVD was also sig-
nificant in most subgroups stratified by demographic
characteristics and selected CVD risk factors and was
similar to that seen for LDL-C.
The strengths of our study include the large sample
size and a long follow-up length in a cohort of adult
participants with diagnosed diabetes. Studies on the
association between non-HDL-C and risk of death from
CVD have been scarce and the findings of limited stu-
dies are inconsistent. As shown in the study conducted
among 313 diabetic patients aged 45 to 64 years in
Table 2 Baseline Characteristics of Adults Aged ≥ 20 Years with Diabetes in the Total Cohort and According to Serum
Non-HDL-C Concentrations, NHANES III (1988-1994)
Variable Total cohort Serum non-HDL-C concentration (mg/dL)
a
35-129 130-189 190-403 P-value
b
Unweighted sample size 1,122 200 563 359
Weighted % 100.0 ± 0.0
c 16.0 ± 2.1 49.2 ± 2.6 34.8 ± 2.7
Follow-up length (yr) 12.4 ± 0.3 12.9 ± 1.2 12.5 ± 0.3 11.9 ± 0.8
Serum non-HDL-C concentration (mg/dL) 174.2 ± 2.9 106.7 ± 3.5 160.2 ± 1.0 225.1 ± 2.6 <0.001
Demographic characteristics
Age (yr) 60.3 ± 0.7 58.4 ± 3.1 60.2 ± 1.0 61.2 ± 0.9 0.39
Male (%) 46.9 ± 2.5 60.9 ± 7.1 49.8 ± 3.7 36.4 ± 3.7 0.006
Non-Hispanic white (%) 74.9 ± 2.0 68.9 ± 5.5 74.4 ± 2.5 78.3 ± 2.9 0.09
Less than high school (%) 42.6 ± 3.0 38.5 ± 6.6 39.8 ± 4.2 48.5 ± 4.0 0.21
Diabetes duration (yr) 9.4 ± 0.4 10.5 ± 1.0 9.0 ± 0.5 9.3 ± 0.6 0.30
CVD risk factors
Current or former smokers (%) 58.9 ± 2.4 58.1 ± 8.0 60.2 ± 3.2 57.5 ± 3.9 0.94
Alcohol consumption (times in previous month) 4.5 ± 0.7 5.9 ± 1.9 4.7 ± 1.2 3.5 ± 1.0 0.26
Body mass index (kg/m
2) 30.1 ± 0.3 27.6 ± 0.6 30.3 ± 0.4 30.9 ± 0.5 <0.001
Leisure-time physical activity (METS) 80.6 ± 6.5 105.4 ± 19.5 81.0 ± 8.3 68.7 ± 8.8 0.10
Systolic blood pressure (mm Hg) 134.0 ± 1.1 129.0 ± 2.4 132.6 ± 1.6 138.3 ± 2.0 0.007
Serum HDL-C (mg/dL) 45.7 ± 0.8 53.1 ± 2.4 45.6 ± 1.0 42.4 ± 1.0 <0.001
Glomerular filtration rate (mL/min per 1.73 m
2) 83.5 ± 1.2 85.9 ± 5.7 86.4 ± 1.3 78.3 ± 1.7 0.20
Serum glycated hemoglobin A1C (%) 7.7 ± 0.1 7.4 ± 0.2 7.6 ± 0.1 7.9 ± 0.2 0.06
C-reactive protein ≥ 3.0 mg/L (%) 50.4 ± 3.4 35.6 ± 6.5 50.0 ± 4.1 57.8 ± 4.4 0.003
Use of prescribed medicine to lower blood cholesterol (%) 9.0 ± 1.3 4.2 ± 1.9 9.1 ± 2.3 11.1 ± 2.7 0.036
Abbreviations: non-HDL-C, non-high-density lipoprotein cholesterol; HDL-C, high-density lipoprotein; METS, metabolic equivalents.
a To convert HDL-C or non-HDL-C concentrations in mg/dL to concentrations in mmol/L, multiply by 0.02586.
b P-values were obtained from t tests for linear trends in the proportions or means across the three non-HDL-C levels.
c All data are weighted percentage ± SE for categorical variables and weighted mean ± SE for continuous variables except for follow-up length (weighted
median ± SE).
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mmol/L (i.e., 204.9 mg/dL) had about 40% increased
risk of death from CHD during a 7-year follow-up [13],
however the association between non-HDL-C and risk
of death from CHD was not statistically significant per-
haps due to a low statistical power. Similarly, a recent
study failed to identify a significant association between
non-HDL-C concentration and risk of mortality from
CVD among 1,565 patients with type 2 diabetes during
an 11-year follow-up [14]. In contrast to the findings of
the previous studies [13,14], the significant and positive
associations between serum non-HDL-C concentration
and risk of death from CVD as shown in our study sug-
gest that serum non-HDL-C concentration could be an
important target in the management of dyslipidemia to
reduce CVD mortality among adults with diabetes.
One of the unique results of our study was the strong
association between non-HDL-C and risk of death from
stroke among adults with diagnosed diabetes. Findings
of previous studies with regard to the association
between non-HDL-C and risk of incident stroke are
mixed among non-diabetic populations. Several studies
showed that non-HDL-C was strongly associated with
risk of fatal and nonfatal ischemic stroke [27-29], while
some other studies showed that non-HDL-C was not
related or weakly related to the risk of incident stroke
[30-32]. To the best of our knowledge, our study was
the first to show the association between non-HDL-C
and risk of death from stroke among people with dia-
betes. These findings have significant clinical implica-
tions because people with diabetes have double the risk
of stroke incidence and risk of mortality after stroke as
seen among people without diabetes [33,34].
While the underlying mechanisms linking non-HDL-C
and risk of mortality from IHD and stroke need to elu-
cidated, non-HDL-C concentration could be a marker of
atherogenic and pathophysiologic effects of multiple
apolipoprotein B-containing lipoproteins and triglycer-
ide-rich lipoproteins including LDL, VLDL, IDL, and
lipoprotein (a). Atherosclerosis begins in childhood and
its development has been correlated with lipoprotein
disorders [35]. Previous studies have shown that non-
HDL-C concentration was highly correlated with coron-
ary atherosclerosis measured at autopsy [36]. Our results
that non-HDL-C was more strongly associated with risk
of death from IHD and stroke than from other CVD
suggest that non-HDL-C may play an important role in
atherosclerosis and cardioembolism because athero-
sclerosis is the established underlying pathologic cause
of IHD and stroke morbidity and mortality [37,38].
Atherogenic dyslipidemia (i.e., hypertriglyceridemia,
low HDL-C concentrations, and elevated small dense
LDL) is frequently present among people with the com-
mon form of type 2 diabetes (i.e., associated with insulin
resistance, hyperinsulinemia, and/or the metabolic syn-
drome) and it has emerged as a critical therapeutic target
in the clinical management of diabetes for the secondary
prevention of macrovascular diseases [39]. About 25.6
million (11.3%) adults aged 20 years and older were esti-
mated to have diabetes in the United States in 2010, with
type 2 diabetes accounting for about 90% to 95% of all
diagnosed cases of diabetes [40]. The clinical guidelines
recommend aggressive treatment of dyslipidemia to
reduce risk of cardiovascular morbidity and mortality in
patients with diabetes [1,41]. American Diabetes Associa-
tion guidelines recommend lowering LDL-C below 100
mg/dL (i.e., 2.6 mmol/L) as the primary goal of therapy
for adults [41,42]. In addition, the NCEP ATP III pro-
poses non-HDL-C as a secondary target of therapy
among people with high triglycerides concentration (i.e.,
≥ 200 mg/dL). The treatment goal for non-HDL-C is set
at 30 mg/dL higher than that for LDL cholesterol [1].
Table 3 Estimated Relative Risk (Hazard Ratio) of Death
from CVD Among U.S. Adults Aged ≥ 20 Years with
Diabetes According to Serum Non-HDL-C Concentrations,
the Third National Health and Nutrition Examination
Survey Linked Mortality Study, 1988-2006
Cause of death Serum non-HDL-C
concentration (mg/dL)
a
35-129 130-189 190-403 P-value
b
Unadjusted risk estimates
Total CVD 1 [Ref] 1.19
(0.71-1.98)
2.19
(1.38- 3.47)
<0.001
IHD 1 [Ref] 1.36
(0.71-2.58)
2.32
(1.30- 4.15)
0.004
Stroke 1 [Ref] 2.91
(0.89-9.57)
5.34
(1.88-15.16)
0.001
Other CVD 1 [Ref] 0.67
(0.31-1.44)
1.53
(0.78- 3.03)
0.21
Adjusted risk estimates
Total CVD 1 [Ref] 1.34
(0.75- 2.39)
2.25
(1.30- 3.91)
0.003
IHD 1 [Ref 1.59
(0.76- 3.32)
2.50
(1.28- 4.89)
0.006
Stroke 1 [Ref] 3.37
(0.95-11.90)
5.81
(1.96-17.25)
0.001
Other CVD 1 [Ref] 0.69
(0.25- 1.88)
1.40
(0.55- 3.55)
0.46
Abbreviations: CVD, cardiovascular disease; CI, confidence interval; IHD,
ischemic heart disease; non-HDL-C, non-high-density lipoprotein cholesterol;
Ref, reference value.
a To convert HDL-C or non-HDL-C concentrations in mg/dL to concentrations
in mmol/L, multiply by 0.02586.
b T-tests were used for testing linear trends. Age was the time scale in the
Cox proportional hazard regression analyses. Relative risks (hazard ratios) and
their 95% CIs were adjusted for sex, race/ethnicity, education attainment,
diabetes duration, body mass index, leisure-time physical activity, smoking
status, alcohol consumption, systolic blood pressure, serum HDL-C
concentration, glomerular filtration rate, C-reactive protein, glycated
hemoglobin A1C, and self-reported use of prescribed medicine to lower blood
cholesterol.
N = 1,122.
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Page 6 of 12Table 4 Relative Risk (Hazard Ratio) of Deaths from Total CVD Attributable to a 10 mg/dL increase in Serum Non-HDL-
C Concentration, Stratified According to Selected Risk Factors, the Third National Health and Nutrition Examination
Survey Linked Mortality Study, 1988-2006
Stratification Variable N (Weighted %) Non-HDL-C
Concentration
(Mean ± SE, mg/dL)
Relative Risk
a (95% CI) P Value for Relative Risk
Estimate (Interaction)
b
Total 1,122 (100.0) 174.25 ± 2.89 1.07 (1.04-1.11) 0.0001
Sex (0.012)
Men 501 (46.9) 165.45 ± 4.40* 1.11 (1.05-1.17) 0.0003
Women 621 (53.1) 182.02 ± 2.69 1.04 (0.99-1.09) 0.098
Age (yr) (0.032)
20-64 560 (58.5) 174.03 ± 4.06 1.12 (1.05-1.19) 0.0005
≥ 65 562 (41.5) 174.55 ± 2.79 1.04 (1.01-1.07) 0.019
Race (0.091)
Non-Hispanic white 424 (74.9) 176.01 ± 3.62 1.09 (1.05-1.14) 0.0001
Non-white 698 (25.1) 169.01 ± 3.04 1.01 (0.97-1.05) 0.68
Education (0.60)
≥ High school 429 (57.4) 170.78 ± 4.67 1.06 (0.99-1.13) 0.098
< High school 693 (42.6) 178.91 ± 2.65 1.09 (1.03-1.14) 0.0022
Diabetes duration (yr) (0.017)
< 10 619 (60.7) 172.86 ± 3.86 1.11 (1.06-1.16) 0.0001
≥ 10 503 (39.3) 176.39 ± 3.21 1.02 (0.97-1.07) 0.43
Follow-up length (yr) (0.0036)
< 10 446 (33.4) 177.81 ± 4.81 1.04 (1.01-1.08) 0.014
≥ 10 676 (66.6) 172.46 ± 3.91 1.17 (1.11-1.23) <0.0001
Smoking status (0.67)
Never smoked 526 (41.1) 174.12 ± 5.46 1.05 (1.00-1.11) 0.045
Current/former smokers 596 (58.9) 174.34 ± 2.26 1.08 (1.02-1.15) 0.015
Alcohol consumption (0.0077)
Consumed alcohol 253 (29.1) 164.10 ± 6.33* 1.20 (1.08-1.33) 0.0009
Did not consume alcohol 869 (70.9) 178.42 ± 2.54 1.06 (1.02-1.09) 0.0011
Body mass index (kg/m
2) (0.52)
< 30 673 (56.7) 166.86 ± 3.96* 1.05 (1.01-1.10) 0.028
≥ 30 449 (43.3) 183.91 ± 2.78 1.10 (1.03-1.17) 0.0038
Leisure-time physical activity (0.52)
Any 745 (73.1) 170.71 ± 3.47* 1.09 (1.04-1.14) 0.0002
None 377 (26.9) 183.87 ± 4.39 1.05 (1.00-1.11) 0.062
Systolic blood pressure (mm Hg) (0.030)
<130 472 (46.2) 167.28 ± 4.97* 1.13 (1.06-1.21) 0.0004
≥130 650 (53.8) 180.24 ± 2.92 1.05 (1.01-1.09) 0.014
Serum HDL-C (mg/dL) (0.75)
Normal 552 (45.6) 162.48 ± 5.09* 1.07 (1.02-1.12) 0.010
Low
c 570 (54.4) 184.11 ± 3.35 1.07 (1.01-1.14) 0.029
Glomerular filtration rate (mL/min per 1.73 m
2) (0.21)
≥ 60.0 904 (83.3) 170.89 ± 3.10* 1.10 (1.05-1.16) 0.0002
< 60.0 218 (16.7) 191.03 ± 6.25 1.02 (0.98-1.06) 0.28
C-reactive protein (mg/L) (0.13)
< 3.0 531 (49.6) 167.90 ± 4.89* 1.11 (1.06-1.16) 0.0001
≥ 3.0 591 (50.4) 180.49 ± 3.13 1.03 (0.98-1.09) 0.19
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Figure 1 Estimated relative risk of death among U.S. adults aged 20 years and older with diagnosed diabetes, the NHANES III Linked
Mortality Study, 1988-2006. The red solid line indicates the fitted relationship between the relative risk of death from total CVD (A), IHD (B),
stroke (C), and other CVD (D) in relation to the continuum of serum non-HDL-C concentrations with a 3-knot cubic regression spline. The blue
dashed lines indicate the 95% confidence intervals surrounding the estimates. Adults with a serum non-HDL-C concentration of 130 mg/dL were
set as the reference group. Relative risks (hazard ratios) and their 95% CIs were adjusted for sex, race/ethnicity, education attainment, diabetes
duration, body mass index, leisure-time physical activity, smoking status, alcohol consumption, systolic blood pressure, serum HDL-C
concentration, glomerular filtration rate, C-reactive protein, glycated hemoglobin A1C, and self-reported use of prescribed medicine to lower
blood cholesterol. N = 1,122. To convert non-HDL-C concentration in mg/dL to mmol/L, multiply by 0.02586.N Abbreviations: CVD, cardiovascular
disease; IHD, ischemic heart disease; NHANES III, Third National Health and Nutrition Examination Survey; Non-HDL-C, non-high-density
lipoprotein cholesterol.
Table 4 Relative Risk (Hazard Ratio) of Deaths from Total CVD Attributable to a 10 mg/dL increase in Serum Non-HDL-
C Concentration, Stratified According to Selected Risk Factors, the Third National Health and Nutrition Examination
Survey Linked Mortality Study, 1988-2006 (Continued)
Serum glycated hemoglobin A1C (%) (0.44)
< 7.0 465 (43.1) 167.66 ± 2.78* 1.08 (1.03-1.13) 0.0039
≥ 7.0 657 (56.9) 179.23 ± 4.06 1.06 (0.99-1.12) 0.076
Abbreviations: CVD, cardiovascular disease; CI, confidence interval; IHD, ischemic heart disease; non-HDL-C, non-high-density lipoprotein cholesterol.
a Relative risks (hazard ratios) and their 95% CIs were adjusted for sex, race/ethnicity, education attainment, diabetes duration, body mass index, leisure-time physical
activity, smoking status, alcohol consumption, systolic blood pressure, serum HDL-C concentration, glomerular filtration rate, C-reactive protein, glycated hemoglobin
A1C, and self-reported use of prescribed medicine to lower blood cholesterol. Age was the time scale in the Cox proportional hazard regression analyses.
b P values were based on results of t tests for the estimates of hazard ratios within each subgroup and Wald c
2-tests for the interaction between serum non-
HDL-C concentration and each stratification variable (shown in bold fonts and in parentheses).
c Defined as <40 mg/dL among men and <50 mg/dL among women. To convert HDL-C or non-HDL-C concentrations in mg/dL to concentrations in mmol/L,
multiply by 0.02586.
* Within each category of stratification variable, mean value with an asterisk is significantly different from the mean value of another category, P = 0.05; t tests
were used to test for equality.
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Page 8 of 12Our results that people with a serum non-HDL-C con-
centration of 190 mg/dL or above had a greater than
two-fold increased risk of death from CVD as those with
a concentration below 130 mg/dL provide further sup-
port on the use of 190 mg/dL as clinically important
threshold value of non-HDL-C concentration in associa-
tion with excess risk of death from CVD and 130 mg/dL
as a therapeutic goal.
Our results of subgroup analyses highlight the consis-
tency in the association between serum non-HDL-C
concentration and risk of death from CVD across each
level of most demographic variables and selected CVD
risk factors. It is noteworthy, however, that the strength
in the association between non-HDL-C and risk of
death from CVD may vary by sex, age, diabetes dura-
tion, length of follow-up, and alcohol consumption
because our data clearly demonstrated that there was a
significant interaction between these variables and non-
HDL-C on the risk of death from CVD. Men have a
higher serum non-HDL-C concentration than women in
the general population [43]. However, among people
with diagnosed diabetes, men have a lower serum non-
HDL-C concentration than women, perhaps attributable
in part to a higher proportion of men using prescribed
medicine to lower blood cholesterol as shown in our
study. The variations in the mean serum non-HDL-C
concentration and its association with risk of death
from CVD between men and women suggest that differ-
ent cutoff values of non-HDL-C may be needed in clini-
cal practice and research.
It is also worth commenting on the variations in the
association between non-HDL-C and risk of death from
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Figure 2 Hazard ratios of death among U.S. adults aged 20 years and older with diagnosed diabetes, the NHANES III Linked Mortality
Study, 1988-2006. Unadjusted (blue dots) and adjusted (red dots) hazard ratios of death from total CVD (A), IHD (B), stroke (C), and other CVD
(D) and their 95% CIs (high-low lines) were adjusted for sex, race/ethnicity, education attainment, diabetes duration, body mass index, leisure-
time physical activity, smoking status, alcohol consumption, systolic blood pressure, serum HDL-C concentration, glomerular filtration rate, C-
reactive protein, glycated hemoglobin A1C, and self-reported use of prescribed medicine to lower blood cholesterol. Adults with a serum non-
HDL-C concentration below 130 mg/dL were set as the reference group. N = 1,122. To convert non-HDL-C concentration in mg/dL to mmol/L,
multiply by 0.02586. Abbreviations: CVD, cardiovascular disease; IHD, ischemic heart disease; NHANES III, Third National Health and Nutrition
Examination Survey; Non-HDL-C, non-high-density lipoprotein cholesterol.
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Page 9 of 12CVD across age, diabetes duration, and follow-up length
in the cohort. Our results that the associations appeared
to be stronger among people aged 20 to 64 years than
those aged 65 years and older, among people with a dia-
betes diagnosis less than 10 years than those with dia-
betes 10 years and above, and among those with a
follow-up length 10 years and above than those with a
follow-up length less than 10 years all indicate that the
effect of serum non-HDL-C on the risk of CVD mortal-
ity may be related to a prolonged exposure. In addition,
these variations may be helpful in explaining the differ-
ences in the findings of previous studies that differ in
demographic characteristics and follow-up length
[13,14].
Our results are subject to several limitations. First,
because only a single measurement of serum non-HDL-
C concentration at baseline was available, bias from
regression toward the mean may have led us to underes-
timate the strength for the associations. Second, the
diagnosis of diabetes was ascertained by participants’
self-report and there could be some misclassification
biases. According to a previous study, the agreement
between self-report and medical record was substantial
(kappa = 0.76) and the sensitivity was high (75%) for
diabetes diagnosis [44]. Thus, the impact of the misclas-
sification bias in diabetes status on our results could be
minimal. Third, because serum LDL-C concentration
was estimated using a subsample of adults who had
fasted at least eight hours, the sample size for compar-
ing the relative risk of death from CVD between non-
HDL-C and LDL-C was relatively small. Future research
using a larger sample may be needed to confirm our
results that non-HDL-C performed similarly to LDL-C
in relation to CVD mortality.
In conclusion, our findings, based on data from a large
representative sample of U.S. adults with diabetes,
showed that higher serum non-HDL-C concentrations
were significantly associated with the increased risk of
death from CVD, particularly from IHD and stroke.
They also showed that the positive association was inde-
pendent of traditional and emerging CVD risk factors.
Non-HDL-C may be a more useful target in this popula-
tion than LDL-C as it reflects all apolipoprotein B100-
containing atherogenic lipid particles, it can be assessed
at all levels of triglyceride, and it can be measured
Table 5 Estimated Relative Risk (Hazard Ratio) of Death
from CVD Among U.S. Adults Aged ≥20 Years with Both
Diagnosed Diabetes and Undiagnosed Diabetes
(A1C≥6.5%) According to Serum Non-HDL-C
Concentrations, the Third National Health and Nutrition
Examination Survey Linked Mortality Study, 1988-2006
Cause of death Serum non-HDL-C
concentration (mg/dL)
35-129 130-189 190-403 P-value
a
Unadjusted risk estimates
Total CVD 1 [Ref] 0.93
(0.63-1.38)
1.55
(1.03-2.34)
0.033
Ischemic heart disease 1 [Ref] 0.87
(0.5-1.51)
1.44
(0.87-2.38)
0.14
Stroke 1 [Ref] 3.34
(1.17-9.52)
3.87
(1.54-9.76)
0.0033
Other CVD 1 [Ref] 0.66
(0.32-1.36)
1.42
(0.74-2.71)
0.28
Adjusted risk estimates
Total CVD 1 [Ref] 0.95
(0.63-1.45)
1.53
(0.95-2.45)
0.072
Ischemic heart disease 1 [Ref] 0.91
(0.50-1.65)
1.51
(0.88-2.59)
0.13
Stroke 1 [Ref] 3.44
(1.23-9.63)
4.33
(1.63-11.49)
0.0026
Other CVD 1 [Ref] 0.58
(0.26-1.31)
1.01
(0.45-2.24)
0.99
Abbreviations: CVD, cardiovascular disease; non-HDL-C, non-high-density
lipoprotein cholesterol; Ref, reference value.
a T-tests were used for testing linear trends. Age was the time scale in the
Cox proportional hazard regression analyses. Relative risks (hazard ratios) and
their 95% CIs were adjusted for sex, race/ethnicity, education attainment,
diabetes duration, body mass index, leisure-time physical activity, smoking
status, alcohol consumption, systolic blood pressure, serum HDL-C
concentration, glomerular filtration rate, C-reactive protein, and self-reported
use of prescribed medicine to lower blood cholesterol.
N = 1,647 participants with diagnosed diabetes and undiagnosed diabetes (i.
e., glycated hemoglobin A1C ≥ 6.5%).
Table 6 Estimated Relative Risk (Hazard Ratio) of Death
from CVD Attributable to a 10 mg/dL Increase in Serum
Non-HDL-C Concentration and a 10 mg/dL Increase in
Serum LDL-C Concentration Among U.S. Adults Aged
≥ 20 Years with Diabetes, the Third National Health and
Nutrition Examination Survey Linked Mortality Study,
1988-2006
Cause of death Non-HDL-C LDL-C
Unadjusted risk estimates
Total CVD 1.07 (0.97-1.18) 1.06 (0.95-1.19)
Ischemic heart disease 1.14 (1.01-1.29) 1.14 (0.99-1.32)
Stroke 1.09 (0.93-1.29) 1.08 (0.92-1.27)
Other CVD 0.93 (0.82-1.04) 0.89 (0.78-1.01)
Adjusted risk estimates
a
Total CVD 1.07 (0.98-1.16) 1.09 (0.99-1.19)
Ischemic heart disease 1.16 (1.03-1.29) 1.21 (1.05-1.38)
Stroke 1.05 (0.93-1.18) 1.11 (0.94-1.30)
Other CVD 0.89 (0.78-1.02) 0.87 (0.76-1.01)
Abbreviations: CVD, cardiovascular disease; non-HDL-C, non-high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
a Age was the time scale in the Cox proportional hazard regression analyses.
Relative risks (hazard ratios) and their 95% CIs were adjusted for sex, race/
ethnicity, education attainment, diabetes duration, body mass index, leisure-
time physical activity, smoking status, alcohol consumption, systolic blood
pressure, serum HDL-C concentration, glomerular filtration rate, C-reactive
protein, glycated hemoglobin A1C, and self-reported use of prescribed
medicine to lower blood cholesterol.
N = 366 adults who attended the morning session of a Mobile Examination
Center, had fasted at least 8 hours, and had a valid LDL-C value.
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Page 10 of 12without fasting. Clinical trials in those with diabetes
should consider non-HDL-C as a primary or secondary
endpoint.
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